ALIM | Alimera Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	1.35
Implied Volatility	64.10%
IV Rank	1.02%
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2019-11-04

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	6.94
EPS	N/A
1YR Price Target	8.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	154
Country	USA
Website	ALIM

Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.

ALIM's peers: AQST, AYTU, CPHI, CPIX, DERM, DRRX, YCBD, COSM, KALA, KMDA, ORGO, PTPI, RDHL, SBFM, SCYX, SIGA, SNOA, SXTC, SHPH, LFCR

*Chart delayed

Analyzing fundamentals for ALIM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is very weak. For more detailed analysis please see ALIM Fundamentals page.

Watching at ALIM technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on ALIM Technicals page.